Natalya M. Savushkina
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Natalya M. Savushkina has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Aleksander M. Lila
V.A. Nasonova Research Institute of Rheumatology; Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of the Russian Federation
18 shared publications - Ekaterina A. Strebkova
Nasonova Research Institute of Rheumatology
18 shared publications - Elena A. Taskina
Nasonova Research Institute of Rheumatology
18 shared publications - Lyudmila Ivanovna Alekseeva
V.A. Nasonova Research Institute of Rheumatology
18 shared publications - Natalia G. Kashevarova
V.A. Nasonova Research Institute of Rheumatology
18 shared publications - Evgeniia P. Sharapova
V.A. Nasonova Research Institute of Rheumatology
15 shared publications
Latest Publications
- Open Access
- 17 August 2026
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 20 (4) , 67-74
Prospective study of the effect of a glucosamine hydrochloride and chondroitin sulfate combination on systemic inflammation parameters in patients with knee osteoarthritis (report 2)
Objective: to evaluate the effect of a combination of glucosamine hydrochloride (GH) 500 mg and chondroitin sulfate (CS) 500 mg on systemic inflammation parameters in patients with inflammatory (IP) and metabolic (MP) phenotypes of knee osteoarthritis (OA). Material and methods. At the first stage of the study, which lasted 3 months, the efficacy of Artra® was evaluated in 70 patients with a definite diagnosis of stage II–III knee OA and walking pain ≥4 points on the numerical rating scale (NRS). All patients received Artra® and topical nonsteroidal anti-inflammatory drugs as needed. Changes in NRS pain, the WOMAC index, and patient global health assessment using a visual analog scale were determined. At the second stage of the study, the efficacy of Artra® was analyzed in two patient subgroups: those with the metabolic phenotype of OA (n=29) and those with the inflammatory phenotype of OA (n=12). CRP levels were measured in all patients at visits 1 and 3; in 22 patients, serum concentrations of 17 cytokines, chemokines, and growth factors were also measured at baseline and after 3 months. Results and discussion . After a 3-month course of therapy, a statistically significant (pConclusion . Artra® is characterized by a significant symptomatic effect, including analgesic and anti-inflammatory effects, in patients with the OA phenotypes that are most difficult to treat, namely MP and IP. Our study confirmed the ability of the drug to reduce the production of several proinflammatory cytokines and chemokines that play an important role in the development and progression not only of OA but also of other agerelated diseases, including metabolic syndrome. The findings indicate that the drug can affect different components of OA pathogenesis, which supports its use in patients with comorbidities.
- 17 August 2026
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 20 (4) , 67-74
Open AccessProspective study of the effect of a glucosamine hydrochloride and chondroitin sulfate combination on systemic inflammation parameters in patients with knee osteoarthritis (report 2)
Objective: to evaluate the effect of a combination of glucosamine hydrochloride (GH) 500 mg and chondroitin sulfate (CS) 500 mg on systemic inflammation parameters in patients with inflammatory (IP) and metabolic (MP) phenotypes of knee osteoarthritis (OA). Material and methods. At the first stage of the study, which lasted 3 months, the efficacy of Artra® was evaluated in 70 patients with a definite diagnosis of stage II–III knee OA and walking pain ≥4 points on the numerical rating scale (NRS). All patients received Artra® and topical nonsteroidal anti-inflammatory drugs as needed. Changes in NRS pain, the WOMAC index, and patient global health assessment using a visual analog scale were determined. At the second stage of the study, the efficacy of Artra® was analyzed in two patient subgroups: those with the metabolic phenotype of OA (n=29) and those with the inflammatory phenotype of OA (n=12). CRP levels were measured in all patients at visits 1 and 3; in 22 patients, serum concentrations of 17 cytokines, chemokines, and growth factors were also measured at baseline and after 3 months. Results and discussion . After a 3-month course of therapy, a statistically significant (pConclusion . Artra® is characterized by a significant symptomatic effect, including analgesic and anti-inflammatory effects, in patients with the OA phenotypes that are most difficult to treat, namely MP and IP. Our study confirmed the ability of the drug to reduce the production of several proinflammatory cytokines and chemokines that play an important role in the development and progression not only of OA but also of other agerelated diseases, including metabolic syndrome. The findings indicate that the drug can affect different components of OA pathogenesis, which supports its use in patients with comorbidities.
- 30 June 2026
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 64 (3)
Hyperuricemia and osteoarthritis: Aspects of immunobiochemical interaction
The aim of this single‑center study was to investigate the relationship between hyperuricemia (HU) and biochemical and immunological parameters in patients with knee osteoarthritis (KOA). Materials and methods . The study included 255 patients aged 40–75 years with a confirmed diagnosis of KOA, Kellgren – Lawrence radiological stages I–III, who provided informed consent. The mean age of the patients was 53.0±10.5 years, body mass index (BMI) was 28.8±6.7 kg/m 2 , and the median disease duration was 2 [0.8; 7] years. The following assessments were performed: questionnaire survey, laboratory testing, standard radiography, knee ultrasound, magnetic resonance imaging (MRI) of the target joint, and dual-energy X‑ray absorptiometry of the axial skeleton. Results . HU was detected in 16.9 % of cases. These patients exhibited significantly higher values ( p < 0.05 in all cases) for: pain on the visual analogue scale, total WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) score, including all its components, and general health status, as well as worse scores on the KOOS (Knee injury and Osteoarthritis Outcome Score), compared with participants without HU. Furthermore, elevated uric acid levels were significantly associated with higher incidence of synovitis, neuropathic pain component, advanced radiological stages, and more severe joint structural damage on MRI (WORMS (WholeOrgan Magnetic Resonance Imaging Score)). However, after adjusting for BMI and waist circumference (WC), these differences lost statistical significance. At the same time, patients with HU showed higher bone mineral density values in the proximal femur and a higher prevalence of coronary artery disease. Additionally, associations were found with higher levels of triglycerides, creatinine, alkaline phosphatase, and lower levels of high-density lipoprotein ( p < 0.05 in all cases). No associations were found with pro- and anti-inflammatory cytokines (interleukin (IL) 1β, IL-6, IL-10, IL-34), metalloproteinase (MMP) 3, MMP-9, markers of cartilage and bone tissue degradation (CTX-I, CTX-II, COMP), or C‑reactive protein. Conclusion . The relationship between HU and KOA severity is most likely indirect and is determined by excess body weight and visceral obesity (as indicated by WC). The lack of associations between HU and CRP levels, pro‑inflammatory cytokines, and cartilage degradation markers suggests that uric acid does not have a direct effect on these parameters in patients with KOA.
- 30 June 2026
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 64 (3)
Hyperuricemia and osteoarthritis: Aspects of immunobiochemical interaction
The aim of this single‑center study was to investigate the relationship between hyperuricemia (HU) and biochemical and immunological parameters in patients with knee osteoarthritis (KOA). Materials and methods . The study included 255 patients aged 40–75 years with a confirmed diagnosis of KOA, Kellgren – Lawrence radiological stages I–III, who provided informed consent. The mean age of the patients was 53.0±10.5 years, body mass index (BMI) was 28.8±6.7 kg/m 2 , and the median disease duration was 2 [0.8; 7] years. The following assessments were performed: questionnaire survey, laboratory testing, standard radiography, knee ultrasound, magnetic resonance imaging (MRI) of the target joint, and dual-energy X‑ray absorptiometry of the axial skeleton. Results . HU was detected in 16.9 % of cases. These patients exhibited significantly higher values ( p < 0.05 in all cases) for: pain on the visual analogue scale, total WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) score, including all its components, and general health status, as well as worse scores on the KOOS (Knee injury and Osteoarthritis Outcome Score), compared with participants without HU. Furthermore, elevated uric acid levels were significantly associated with higher incidence of synovitis, neuropathic pain component, advanced radiological stages, and more severe joint structural damage on MRI (WORMS (WholeOrgan Magnetic Resonance Imaging Score)). However, after adjusting for BMI and waist circumference (WC), these differences lost statistical significance. At the same time, patients with HU showed higher bone mineral density values in the proximal femur and a higher prevalence of coronary artery disease. Additionally, associations were found with higher levels of triglycerides, creatinine, alkaline phosphatase, and lower levels of high-density lipoprotein ( p < 0.05 in all cases). No associations were found with pro- and anti-inflammatory cytokines (interleukin (IL) 1β, IL-6, IL-10, IL-34), metalloproteinase (MMP) 3, MMP-9, markers of cartilage and bone tissue degradation (CTX-I, CTX-II, COMP), or C‑reactive protein. Conclusion . The relationship between HU and KOA severity is most likely indirect and is determined by excess body weight and visceral obesity (as indicated by WC). The lack of associations between HU and CRP levels, pro‑inflammatory cytokines, and cartilage degradation markers suggests that uric acid does not have a direct effect on these parameters in patients with KOA.
- 24 June 2026
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 20 (3)
Approaches to therapy of the metabolic phenotype of osteoarthritis: efficacy of a combination of glucosamine and chondroitin sulfate supplemented with undenatured type 2 collagen, B vitamins, gingerol, and ascorbic acid
- 24 June 2026
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 20 (3)
Approaches to therapy of the metabolic phenotype of osteoarthritis: efficacy of a combination of glucosamine and chondroitin sulfate supplemented with undenatured type 2 collagen, B vitamins, gingerol, and ascorbic acid
- Open Access
- 22 April 2026
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 20 (2) , 74-81
Efficacy and safety of complex therapy for knee osteoarthritis using a combination of chondroitin sulfate and glucosamine, as well as intra-articular administration of a medical device containing polyacrylamide gel
Objective: to evaluate the efficacy and safety of complex therapy for knee osteoarthritis (OA) using a combination of chondroitin sulfate (CS) and glucosamine (G), as well as intra-articular (IA) administration of a medical device (MD) containing polyacrylamide gel (PAAG). Material and methods. The study included 22 patients aged 40–75 years with definite knee OA, radiographic stage II–III. Median age was 64.5 [59.0; 68.0] years. All patients received comprehensive therapy: a single IA injection of 4.0 ml of the PAAG-containing MD into the target knee in combination with oral CS (800 mg/day) and G (1000 mg/day) for 6 months. Total follow-up duration was 9 months (6 months of treatment and 3 months of follow-up). Results and discussion. During complex therapy, a significant reduction in knee pain intensity on the visual analog scale was observed, along with improvement in all WOMAC components, patient global assessment of health status, the Lequesne index, and quality of life according to EQ-5D (pConclusion. The study results confirm the significant efficacy and safety of a complex approach to OA therapy, including the use of a combination of disease-modifying drugs for OA and IA administration of an MD containing PAAG.
- 22 April 2026
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 20 (2) , 74-81
Open AccessEfficacy and safety of complex therapy for knee osteoarthritis using a combination of chondroitin sulfate and glucosamine, as well as intra-articular administration of a medical device containing polyacrylamide gel
Objective: to evaluate the efficacy and safety of complex therapy for knee osteoarthritis (OA) using a combination of chondroitin sulfate (CS) and glucosamine (G), as well as intra-articular (IA) administration of a medical device (MD) containing polyacrylamide gel (PAAG). Material and methods. The study included 22 patients aged 40–75 years with definite knee OA, radiographic stage II–III. Median age was 64.5 [59.0; 68.0] years. All patients received comprehensive therapy: a single IA injection of 4.0 ml of the PAAG-containing MD into the target knee in combination with oral CS (800 mg/day) and G (1000 mg/day) for 6 months. Total follow-up duration was 9 months (6 months of treatment and 3 months of follow-up). Results and discussion. During complex therapy, a significant reduction in knee pain intensity on the visual analog scale was observed, along with improvement in all WOMAC components, patient global assessment of health status, the Lequesne index, and quality of life according to EQ-5D (pConclusion. The study results confirm the significant efficacy and safety of a complex approach to OA therapy, including the use of a combination of disease-modifying drugs for OA and IA administration of an MD containing PAAG.
- 22 December 2025
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 19 (6)
Prospective study assessing the effects of the novel pharmaconutraceutical Revocca (unsaponifiable compounds of avocado and soybeans in a 1:2 ratio, rosehip fruit extract, resveratrol, zinc citrate) on the clinical manifestations of osteoarthritis (VECTOR)
Objective: to evaluate the effects of the novel pharmaconutraceutical Revocca on the clinical manifestations of osteoarthritis (OA). Material and methods . A 3-month prospective study included 50 women aged 40–75 years (mean age 58.3±10.1 years) with a confirmed diagnosis of knee OA according to ACR criteria, Kellgren–Lawrence grade II–III, with pain on walking ≥40 mm on a visual analogue scale (VAS), who provided written informed consent. The median OA duration was 5 [3; 8] years. A metabolic phenotype of OA was present in 22% of patients, an inflammatory phenotype in 10%, an osteoporotic phenotype in 12%, a mixed phenotype in 26%, while in 30% the phenotype could not be determined. Patients took 2 capsules of the pharmaconutraceutical once daily throughout the observation period. All patients were allowed to use nonsteroidal anti-inflammatory drugs (NSAIDs) “as needed.” Three physician visits (V) were scheduled during the study. Treatment efficacy was assessed by the dynamics of pain intensity in the target knee joint on walking (VAS), WOMAC index, KOOS scale, and EQ-5D questionnaire scores. Additional assessments included the patient’s VAS global health assessment, physician’s and patient’s assessments of treatment efficacy, and the need for NSAIDs. Results and discussion . After 1 month of therapy, a statistically significant positive change was observed in all evaluated parameters (pConclusion. The study results indicate a rapid and pronounced clinical effect of Revocca in patients with various OA phenotypes.
- 22 December 2025
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 19 (6)
Prospective study assessing the effects of the novel pharmaconutraceutical Revocca (unsaponifiable compounds of avocado and soybeans in a 1:2 ratio, rosehip fruit extract, resveratrol, zinc citrate) on the clinical manifestations of osteoarthritis (VECTOR)
Objective: to evaluate the effects of the novel pharmaconutraceutical Revocca on the clinical manifestations of osteoarthritis (OA). Material and methods . A 3-month prospective study included 50 women aged 40–75 years (mean age 58.3±10.1 years) with a confirmed diagnosis of knee OA according to ACR criteria, Kellgren–Lawrence grade II–III, with pain on walking ≥40 mm on a visual analogue scale (VAS), who provided written informed consent. The median OA duration was 5 [3; 8] years. A metabolic phenotype of OA was present in 22% of patients, an inflammatory phenotype in 10%, an osteoporotic phenotype in 12%, a mixed phenotype in 26%, while in 30% the phenotype could not be determined. Patients took 2 capsules of the pharmaconutraceutical once daily throughout the observation period. All patients were allowed to use nonsteroidal anti-inflammatory drugs (NSAIDs) “as needed.” Three physician visits (V) were scheduled during the study. Treatment efficacy was assessed by the dynamics of pain intensity in the target knee joint on walking (VAS), WOMAC index, KOOS scale, and EQ-5D questionnaire scores. Additional assessments included the patient’s VAS global health assessment, physician’s and patient’s assessments of treatment efficacy, and the need for NSAIDs. Results and discussion . After 1 month of therapy, a statistically significant positive change was observed in all evaluated parameters (pConclusion. The study results indicate a rapid and pronounced clinical effect of Revocca in patients with various OA phenotypes.
- Open Access
- 18 October 2025
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 19 (5) , 34-40
Early-stage knee osteoarthritis: assessment of structural changes using imaging methods
Objective. To identify magnetic resonance imaging (MRI) features of structural changes in patients with early-stage knee osteoarthritis (OA) using the Whole-Organ Magnetic Resonance Imaging Score (WORMS).Material and methods. The study included 78 women aged 35–68 years with knee pain lasting no longer than 1 year and minimal radiographic changes according to Kellgren–Lawrence grade 0–II (without joint space narrowing). A standardized individual record was completed for each patient, including anthropometric data (body mass index, BMI), disease history, results of clinical examination, assessment of knee pain by visual analogue scale, global health assessment by the patient, WOMAC index, KOOS scale, DN4 questionnaire, and information on comorbidities. All patients underwent standard radiography, ultrasound, knee MRI, and laboratory testing. MRI images were assessed using WORMS.Results and discussion. At the early stage of OA, the most common MRI findings were synovitis (96.2%), cartilage changes (93.6%), and degenerative meniscal lesions (up to 89.7%). Osteophytes, mostly of small size, were detected in 38.5% of patients; osteitis and subchondral cysts were relatively rare (Conclusion. MRI is a valuable tool for visualizing structural changes in early OA. In patients with such clinical risk factors as older age, increased BMI, MS, pain, and clinically detected synovitis, MRI can be considered a justified method for verifying early OA signs. Significant correlations between MRI changes and clinical parameters provide prospects for improving early OA diagnosis.
- 18 October 2025
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 19 (5) , 34-40
Open AccessEarly-stage knee osteoarthritis: assessment of structural changes using imaging methods
Objective. To identify magnetic resonance imaging (MRI) features of structural changes in patients with early-stage knee osteoarthritis (OA) using the Whole-Organ Magnetic Resonance Imaging Score (WORMS).Material and methods. The study included 78 women aged 35–68 years with knee pain lasting no longer than 1 year and minimal radiographic changes according to Kellgren–Lawrence grade 0–II (without joint space narrowing). A standardized individual record was completed for each patient, including anthropometric data (body mass index, BMI), disease history, results of clinical examination, assessment of knee pain by visual analogue scale, global health assessment by the patient, WOMAC index, KOOS scale, DN4 questionnaire, and information on comorbidities. All patients underwent standard radiography, ultrasound, knee MRI, and laboratory testing. MRI images were assessed using WORMS.Results and discussion. At the early stage of OA, the most common MRI findings were synovitis (96.2%), cartilage changes (93.6%), and degenerative meniscal lesions (up to 89.7%). Osteophytes, mostly of small size, were detected in 38.5% of patients; osteitis and subchondral cysts were relatively rare (Conclusion. MRI is a valuable tool for visualizing structural changes in early OA. In patients with such clinical risk factors as older age, increased BMI, MS, pain, and clinically detected synovitis, MRI can be considered a justified method for verifying early OA signs. Significant correlations between MRI changes and clinical parameters provide prospects for improving early OA diagnosis.
- Open Access
- 18 October 2025
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 19 (5) , 74-83
Evaluation of the effect of a combination of glucosamine and chondroitin sulfate supplemented with native (undenatured) type 2 collagen, ginger extract, B vitamins, and ascorbic acid on the clinical manifestations of different phenotypes of osteoarthritis
Objective. To evaluate the efficacy and safety of Teraflex Ultra compared with Teraflex® in patients with different phenotypes of osteoarthritis (OA).Material and methods. A prospective comparative randomized study included 80 women aged 40–75 years with a confirmed diagnosis of knee OA (Kellgren–Lawrence stages I–III) and pain on walking ≥40 mm on a visual analogue scale (VAS). The study duration was 9 months (6 months of treatment and 3 months of follow-up). Patients were randomized into two groups. Group 1 (n=40) received Theraflex Ultra orally, 2 capsules twice daily. Group 2 (n=40) received Theraflex® orally, 1 capsule three times daily for 3 weeks, followed by 1 capsule twice daily. All patients were allowed to take nonsteroidal anti-inflammatory drugs (NSAIDs) as required: Theraleve 275 (naproxen) up to 3 tablets per day. Treatment efficacy was assessed by changes in pain intensity on the VAS, WOMAC index, KOOS scale, and EQ-5D quality-of-life questionnaire.Results and discussion. The trial demonstrated efficacy of pharmaconutraceutical and the drug in reducing pain on walking (VAS), total WOMAC and its subscales, as well as improving KOOS and EQ-5D scores (pConclusion. The results indicate that Theraflex Ultra provides a faster and more pronounced clinical effect compared with Theraflex® in patients with different phenotypes of OA.
- 18 October 2025
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 19 (5) , 74-83
Open AccessEvaluation of the effect of a combination of glucosamine and chondroitin sulfate supplemented with native (undenatured) type 2 collagen, ginger extract, B vitamins, and ascorbic acid on the clinical manifestations of different phenotypes of osteoarthritis
Objective. To evaluate the efficacy and safety of Teraflex Ultra compared with Teraflex® in patients with different phenotypes of osteoarthritis (OA).Material and methods. A prospective comparative randomized study included 80 women aged 40–75 years with a confirmed diagnosis of knee OA (Kellgren–Lawrence stages I–III) and pain on walking ≥40 mm on a visual analogue scale (VAS). The study duration was 9 months (6 months of treatment and 3 months of follow-up). Patients were randomized into two groups. Group 1 (n=40) received Theraflex Ultra orally, 2 capsules twice daily. Group 2 (n=40) received Theraflex® orally, 1 capsule three times daily for 3 weeks, followed by 1 capsule twice daily. All patients were allowed to take nonsteroidal anti-inflammatory drugs (NSAIDs) as required: Theraleve 275 (naproxen) up to 3 tablets per day. Treatment efficacy was assessed by changes in pain intensity on the VAS, WOMAC index, KOOS scale, and EQ-5D quality-of-life questionnaire.Results and discussion. The trial demonstrated efficacy of pharmaconutraceutical and the drug in reducing pain on walking (VAS), total WOMAC and its subscales, as well as improving KOOS and EQ-5D scores (pConclusion. The results indicate that Theraflex Ultra provides a faster and more pronounced clinical effect compared with Theraflex® in patients with different phenotypes of OA.
- Open Access
- 24 June 2025
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 19 (3) , 56-63
Factors associated with knee pain at early stages of osteoarthritis
Objective: To investigate key risk factors associated with knee pain in early-stage osteoarthritis (OA).Material and methods. The study included 109 women aged 35–75 years with knee pain lasting no more than one year and minimal radiographic changes (Kellgren–Lawrence grades 0–II). For each patient we filled in a personalized case form including anthropometric data, medical history, physical examination findings, pain and health status assessments using visual analog scale (VAS), and questionnaires (WOMAC, KOOS, DN4), along with information on comorbidities. All participants underwent standard knee radiography, ultrasound examination, and laboratory testing.Results and discussion. One in six patients (15%) reported moderate or severe knee pain (≥40 mm on VAS). Patients with more intense pain were older than those with VAS Conclusion. Severe knee pain at early stages of OA is associated with functional impairment according to WOMAC, clinical synovitis, ultrasounddetected osteophytes, and metabolic syndrome. These risk factors and the developed predictive model may be useful for planning individualized preventive and therapeutic strategies in OA patients.
- 24 June 2025
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 19 (3) , 56-63
Open AccessFactors associated with knee pain at early stages of osteoarthritis
Objective: To investigate key risk factors associated with knee pain in early-stage osteoarthritis (OA).Material and methods. The study included 109 women aged 35–75 years with knee pain lasting no more than one year and minimal radiographic changes (Kellgren–Lawrence grades 0–II). For each patient we filled in a personalized case form including anthropometric data, medical history, physical examination findings, pain and health status assessments using visual analog scale (VAS), and questionnaires (WOMAC, KOOS, DN4), along with information on comorbidities. All participants underwent standard knee radiography, ultrasound examination, and laboratory testing.Results and discussion. One in six patients (15%) reported moderate or severe knee pain (≥40 mm on VAS). Patients with more intense pain were older than those with VAS Conclusion. Severe knee pain at early stages of OA is associated with functional impairment according to WOMAC, clinical synovitis, ultrasounddetected osteophytes, and metabolic syndrome. These risk factors and the developed predictive model may be useful for planning individualized preventive and therapeutic strategies in OA patients.
- Open Access
- 8 June 2025
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 97 (5) , 434-442
Relationship between vitamin D and osteoarthritis
Background. Osteoarthritis (OA) is a common joint disease and one of the leading causes of disability worldwide. The role of vitamin D in the etiology and development of OA is still unclear, but it may be important for both diagnosis and timely therapy. Aim. To evaluate the relationship of vitamin D levels with clinical and instrumental parameters in OA in a cross-sectional study. Materials and methods. The study included 171 patients aged 40–75 with confirmed knee OA according to the American College of Rheumatology (ACR) classification, stage I–III (according to Kellgren and Lawrence). All patients signed informed consent. The mean age was 53.5±9.94 years, body mass index (BMI) was 29.8±6.4 kg/m2, and disease duration was 3 [1; 7] years. For each patient, a case record form was filled out, including anthropometric indicators, medical history, clinical examination data, an assessment of knee joint pain according to the Visual Analog Scale (VAS), WOMAC, and the patient's general health condition (PGHC). All patients underwent standard radiography, knee ultrasound examination and magnetic resonance imaging (MRI) (WORMS), densitometry of the lumbar spine and femoral neck, and laboratory tests. Statistical processing of the data was performed using the Statistica 10 software. Results. Normal vitamin D values (≥30 ng/mL) were found in 62 (36.3%) patients, low levels (30 ng/mL) in 109 (63.7%) patients, insufficiency (30 ng/mL and 20 ng/mL) in 66 (38.6%) patients, and deficiency (20 ng/mL) in 43 (25.1%). Patients were divided into three groups according to the presence or absence of vitamin D insufficiency/deficiency: Group 1 included patients with normal vitamin D levels, Group 2 included patients with insufficiency, and Group 3 included patients with vitamin D deficiency. Patients of the three groups were comparable in age and disease duration but differed significantly in body weight, BMI, and waist measurement (higher in groups with reduced vitamin D values; p0.05). Also, these patients had significantly higher VAS pain scores, total WOMAC and its components (pain, stiffness, and dysfunction), PGHC, and worse KOOS. More patients in Groups 2 and 3 had OA of the hip and hand joints, clinically detected synovitis, flat feet, and quadriceps muscle hypotrophy. Ultrasound examination significantly more often revealed a reduction of cartilage tissue on both the anteromedial and anterolateral surfaces of the knee joint; MRI showed more often osteitis in the medial condyles of the femur and tibia (p0.05 for all values). Conclusion. Our study demonstrated that low blood vitamin D levels (insufficiency/deficiency) were associated with a more severe knee OA. These patients had a large body weight, BMI, higher VAS pain values, WOMAC index (overall and its components), worse KOOS, PGHC, and smaller cartilage sizes in the medial parts of the knee joint (according to ultrasound); such patients were significantly more likely to have osteitis in the medial parts of the femur and tibia according to MRI. Also, stage II and III knee OA and OA of other localizations, clinically detected synovitis, quadriceps hypotrophy, and flat feet were more common.
- 8 June 2025
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 97 (5) , 434-442
Open AccessRelationship between vitamin D and osteoarthritis
Background. Osteoarthritis (OA) is a common joint disease and one of the leading causes of disability worldwide. The role of vitamin D in the etiology and development of OA is still unclear, but it may be important for both diagnosis and timely therapy. Aim. To evaluate the relationship of vitamin D levels with clinical and instrumental parameters in OA in a cross-sectional study. Materials and methods. The study included 171 patients aged 40–75 with confirmed knee OA according to the American College of Rheumatology (ACR) classification, stage I–III (according to Kellgren and Lawrence). All patients signed informed consent. The mean age was 53.5±9.94 years, body mass index (BMI) was 29.8±6.4 kg/m2, and disease duration was 3 [1; 7] years. For each patient, a case record form was filled out, including anthropometric indicators, medical history, clinical examination data, an assessment of knee joint pain according to the Visual Analog Scale (VAS), WOMAC, and the patient's general health condition (PGHC). All patients underwent standard radiography, knee ultrasound examination and magnetic resonance imaging (MRI) (WORMS), densitometry of the lumbar spine and femoral neck, and laboratory tests. Statistical processing of the data was performed using the Statistica 10 software. Results. Normal vitamin D values (≥30 ng/mL) were found in 62 (36.3%) patients, low levels (30 ng/mL) in 109 (63.7%) patients, insufficiency (30 ng/mL and 20 ng/mL) in 66 (38.6%) patients, and deficiency (20 ng/mL) in 43 (25.1%). Patients were divided into three groups according to the presence or absence of vitamin D insufficiency/deficiency: Group 1 included patients with normal vitamin D levels, Group 2 included patients with insufficiency, and Group 3 included patients with vitamin D deficiency. Patients of the three groups were comparable in age and disease duration but differed significantly in body weight, BMI, and waist measurement (higher in groups with reduced vitamin D values; p0.05). Also, these patients had significantly higher VAS pain scores, total WOMAC and its components (pain, stiffness, and dysfunction), PGHC, and worse KOOS. More patients in Groups 2 and 3 had OA of the hip and hand joints, clinically detected synovitis, flat feet, and quadriceps muscle hypotrophy. Ultrasound examination significantly more often revealed a reduction of cartilage tissue on both the anteromedial and anterolateral surfaces of the knee joint; MRI showed more often osteitis in the medial condyles of the femur and tibia (p0.05 for all values). Conclusion. Our study demonstrated that low blood vitamin D levels (insufficiency/deficiency) were associated with a more severe knee OA. These patients had a large body weight, BMI, higher VAS pain values, WOMAC index (overall and its components), worse KOOS, PGHC, and smaller cartilage sizes in the medial parts of the knee joint (according to ultrasound); such patients were significantly more likely to have osteitis in the medial parts of the femur and tibia according to MRI. Also, stage II and III knee OA and OA of other localizations, clinically detected synovitis, quadriceps hypotrophy, and flat feet were more common.
- Open Access
- 20 February 2025
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 97 (1) , 54-64
Experience with the use of undenatured type II collagen in patients with stage III knee osteoarthritis: a multicenter, prospective, double-blind, placebo-controlled, randomized trial
Introduction. Current strategies for treating osteoarthritis (OA) are based on a multimodal approach that includes pharmacological and non-pharmacological methods. Undenatured chicken collagen type II (NK2) is considered safe and effective for maintaining joint health and can be used alone and combined with drugs for OA treatment. Aim. To further evaluate the efficacy of the combination of Artneo containing NK2 in patients with stage III knee OA compared with placebo in a multicenter, prospective, double-blind, placebo-controlled, randomized trial. Materials and methods. The study included 212 patients from 12 centers in the Russian Federation, of whom 50 had radiological stage III knee OA: 41 (82.0%) females and 9 (18.0%) males aged 44 to 75. Using the interactive web response system (IWRS), the study population was randomized into two groups: Group 1 (Artneo group) included 28 patients receiving the drug 1 capsule once a day for 180 days, Group 2 (placebo group) included 22 patients receiving placebo with drug-matched presentation and the same regimen as in Group 1. The effectiveness of therapy was assessed by the change of pain using the Visual Analog Scale, the WOMAC index, KOOS, the EQ-5D quality of life questionnaire, and the need for non-steroidal anti-inflammatory drugs. All patients had a complete blood count, urinalysis, blood chemistry, and ultrasonic examination of the target knee joint. Results. A prospective, double-blind, placebo-controlled, randomized trial demonstrated that Artneo containing NK2 was significantly superior to placebo in all studied parameters, improved all clinical manifestations of OA: reduced pain and stiffness, improved joint function and quality of life, and had a good safety profile. Conclusion. Artneo showed high efficacy and safety in the general population of patients, including those with stage III knee OA.
- 20 February 2025
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 97 (1) , 54-64
Open AccessExperience with the use of undenatured type II collagen in patients with stage III knee osteoarthritis: a multicenter, prospective, double-blind, placebo-controlled, randomized trial
Introduction. Current strategies for treating osteoarthritis (OA) are based on a multimodal approach that includes pharmacological and non-pharmacological methods. Undenatured chicken collagen type II (NK2) is considered safe and effective for maintaining joint health and can be used alone and combined with drugs for OA treatment. Aim. To further evaluate the efficacy of the combination of Artneo containing NK2 in patients with stage III knee OA compared with placebo in a multicenter, prospective, double-blind, placebo-controlled, randomized trial. Materials and methods. The study included 212 patients from 12 centers in the Russian Federation, of whom 50 had radiological stage III knee OA: 41 (82.0%) females and 9 (18.0%) males aged 44 to 75. Using the interactive web response system (IWRS), the study population was randomized into two groups: Group 1 (Artneo group) included 28 patients receiving the drug 1 capsule once a day for 180 days, Group 2 (placebo group) included 22 patients receiving placebo with drug-matched presentation and the same regimen as in Group 1. The effectiveness of therapy was assessed by the change of pain using the Visual Analog Scale, the WOMAC index, KOOS, the EQ-5D quality of life questionnaire, and the need for non-steroidal anti-inflammatory drugs. All patients had a complete blood count, urinalysis, blood chemistry, and ultrasonic examination of the target knee joint. Results. A prospective, double-blind, placebo-controlled, randomized trial demonstrated that Artneo containing NK2 was significantly superior to placebo in all studied parameters, improved all clinical manifestations of OA: reduced pain and stiffness, improved joint function and quality of life, and had a good safety profile. Conclusion. Artneo showed high efficacy and safety in the general population of patients, including those with stage III knee OA.